Thymopentin ameliorates dextran sulfate sodium-induced colitis by triggering the production of IL-22 in both innate and adaptive lymphocytes - Cao, Qiuhua; Gao, Xinghua; Lin, Yanting; Yue, Chongxiu; Wang, Yue; Quan, Fei; Zhang, Zixuan; Liu, Xiaoxuan; Lu, Yuan; Zhan, Yanling; Yang, Hongbao; Li, Xianjing; et al. (Theranostics, 2019)
Keywords: Adaptive Immunity - drug effects; Animals; Atrophy; Biological activity; Blood; Cell Line, Tumor; Colitis, Ulcerative - chemically induced; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - metabolism; Colon; Colon - drug effects; Colon - metabolism; Dextran Sulfate - pharmacology; Disease; Disease Models, Animal; Drugs; Feces - microbiology; Gastrointestinal Microbiome - drug effects; HCT116 Cells; Humans; Immune system; Immunity, Innate - drug effects; Inflammatory bowel disease; Interleukin-22; Interleukins - metabolism; Intestinal Mucosa - drug effects; Intestinal Mucosa - metabolism; Lymphocytes; Lymphocytes - drug effects; Lymphocytes - metabolism; Male; Mice; Mice, Inbred C57BL; Pathology; Research Paper; Sodium; Spleen - drug effects; Spleen - metabolism; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - metabolism; Thymopentin - pharmacology; Thymus gland; DSS-induced colitis; thymopentin; lymphocytes; IL-22; gut microbiota